Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of

Status Recruiting

Clinical Trial Summary

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Clinical Trial Description

Selection of Study Population: The study will enroll 60 adult subjects with transfusion dependent thalassemia receiving deferasirox iron chelation therapy. All eligible subjects will be asked to provide informed consent before participating in the study.

Randomization: Subjects will be randomized in a 1:1 ratio to either continuation of their DFX (control arm) or a combination of DFX plus amlodipine (amlodipine arm).

Treatment: Subjects randomized to the amlodipine arm will receive open label medication (amlodipine) starting at 2.5mg/day and up-titrated by 2.5mg every 7-14 days with the goal of reaching 10mg/day. DFX dose in either arm will not be adjusted unless it was deemed unsafe to remain on the same dose of DFX by the treating physician (significant side effects, lack of efficacy or over-chelation) or T2* drops below 8 ms.

Safety Assessment: Weekly or fortnightly amlodipine titration will be conducted by the research physician in-clinic, based on blood pressure, tolerability, and presence or absence of side-effects.

Adverse Events will be assessed at every visit after the first dose through to the last subject visit.

Efficacy Assessment: the efficacy of amlodipine combined to standard chelation therapy will be assessed by cardiac T2*MRI, done at baseline and 12 months post treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02474420
Study type	Interventional
Source	University Health Network, Toronto
Contact	Rebecca Leroux, RN, CCRP
Phone	+1-416-715-6485
Email	rebecca.leroux@uhn.ca
Status	Recruiting
Phase	N/A
Start date	June 2015
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04423237` - Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
Completed	`NCT04614779` - Long-term Clinical Study of CN128 in Thalassemia Patients	Phase 2
Withdrawn	`NCT03800446` - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood	N/A
Not yet recruiting	`NCT02833493` - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload	N/A
Completed	`NCT02164253` - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients	Phase 2
Completed	`NCT00512226` - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia	N/A
Completed	`NCT00901199` - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload	Phase 2
Recruiting	`NCT00378469` - Study of the Effects of Muscular Activity on Iron Metabolism	N/A
Completed	`NCT00117507` - Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients	Phase 4
Completed	`NCT00138684` - Cytochrome P450 2E1 and Iron Overload	Phase 2
Completed	`NCT03990181` - Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement	N/A
Terminated	`NCT02274233` - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia	Phase 1
Active, not recruiting	`NCT01443195` - Iron Metabolism in Small Pre Term Newborns	N/A
Completed	`NCT01546415` - Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia	Phase 4
Completed	`NCT01572818` - Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients	N/A
Not yet recruiting	`NCT00980421` - Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children	Phase 3
Completed	`NCT01047098` - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation	N/A
Recruiting	`NCT05294471` - Fully Automated High-Throughput Quantitative MRI of the Liver
Completed	`NCT03591575` - Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children	Phase 4
Active, not recruiting	`NCT00907283` - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients — CANALI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms